Personalized anticoagulant therapy in venous thromboembolism: current role of direct oral anticoagulants, unmet clinical needs, and future perspectives on Factor XI inhibition
Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, remains a major cause of morbidity and mortality worldwide. The introduction of direct oral anticoagulants (DOACs) has transformed the management of VTE by providing effective and convenient alternatives to vitamin K antagonists. Ho...